# Junta clínica — PT-pseudo_20ba3f0f6ca0 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_20ba3f0f6ca0",
  "pid": "PT-pseudo_20ba3f0f6ca0",
  "task": 1,
  "psa": 4.8,
  "age": 65,
  "months": 3,
  "pirads": "4",
  "psad": 0.086,
  "psav": 0.35,
  "psap": 3.8,
  "vol": 56.0,
  "dre": "Nodus",
  "bx": "None",
  "cspca": 0.7257912,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 4.8 ng/mL. PI-RADS 4. PSAD 0.09. Prostate volume 56 mL. DRE nodus. csPCa 0.73.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "76 kg",
    "height": "188 cm",
    "bmi": "21.5",
    "bp": "131/58 mmHg",
    "hr": "71 bpm",
    "smoking": "Ex-smoker (11 pack-yr, quit 2023)",
    "last_dental": "6 mo ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "01 Jan 2025",
  "enc_ref": "Dr. C. Peters (GP)",
  "enc_type": "Follow-up - PSA + MRI",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "A recent elevation of prostate-specific antigen to 4.8 ng/mL, coupled with a multiparametric MRI conducted at Jeroen Bosch Ziekenhuis, prompted this consultation."
    },
    {
      "s": "History",
      "t": "A semi-retired musician with a smoking history of 11 pack-years (cessation in 2023) seeks evaluation for a progressively rising PSA and recent imaging results. He reports zero lower urinary tract symptoms, denies haematuria, bone pain, or unexplained weight loss, and maintains a daily 45-minute walking routine alongside a modest alcohol intake of roughly 2 units weekly. Following a recent move, he now shares a residence with his sister, who acts as his next of kin, while his marital status remains married though he currently lives apart from his spouse. Past medical encounters include a routine audiology assessment for mild hearing loss and a dermatology visit for actinic keratosis surveillance; otherwise, his health history is clear, with no comorbidities and no active medications. His prior biopsy bucket remains None. He relies on written summaries during consultations due to mild hearing impairment."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: firm, mobility: unrestricted, asymmetry: Nodus palpable in the right mid-gland peripheral zone. Abdominal and cardiovascular assessments show no abnormalities, recording a blood pressure of 131/58 mmHg and a regular heart rate of 71 bpm. Peripheral lymphadenopathy and hepatosplenomegaly are absent."
    }
  ],
  "occupation": "musician (semi-retired)",
  "marital": "Married",
  "living": "Recently relocated; lives with sister",
  "next_of_kin": "Sibling (sister)",
  "recent_other": [
    "Audiology — hearing test",
    "Dermatology — actinic keratosis check"
  ],
  "alcohol": "2 units / week",
  "exercise": "Walking 45 min/day",
  "ipss": "IPSS score: 0/35 (mild LUTS)",
  "admin": "Hard of hearing — speak clearly; prefers written summaries.",
  "mri_hospital": "Jeroen Bosch Ziekenhuis ('s-Hertogenbosch)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_20ba3f0f6ca0
Task: 1

Encounter: Urology - outpatient on 01 Jan 2025.
Referrer: Dr. C. Peters (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 65-year-old male
  - PSA: 4.8 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.086 ng/mL²
  - PSA velocity: 0.35 ng/mL/yr
  - Prior PSA: 3.8 ng/mL
  - Prostate volume: 56.0 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7257912 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 4.8 ng/mL. PI-RADS 4. PSAD 0.09. Prostate volume 56 mL. DRE nodus. csPCa 0.73.

Vitals: weight 76 kg, height 188 cm, BMI 21.5, BP 131/58 mmHg, HR 71 bpm. Smoking: Ex-smoker (11 pack-yr, quit 2023).

Chief complaint: A recent elevation of prostate-specific antigen to 4.8 ng/mL, coupled with a multiparametric MRI conducted at Jeroen Bosch Ziekenhuis, prompted this consultation.

History: A semi-retired musician with a smoking history of 11 pack-years (cessation in 2023) seeks evaluation for a progressively rising PSA and recent imaging results. He reports zero lower urinary tract symptoms, denies haematuria, bone pain, or unexplained weight loss, and maintains a daily 45-minute walking routine alongside a modest alcohol intake of roughly 2 units weekly. Following a recent move, he now shares a residence with his sister, who acts as his next of kin, while his marital status remains married though he currently lives apart from his spouse. Past medical encounters include a routine audiology assessment for mild hearing loss and a dermatology visit for actinic keratosis surveillance; otherwise, his health history is clear, with no comorbidities and no active medications. His prior biopsy bucket remains None. He relies on written summaries during consultations due to mild hearing impairment.

Physical examination: DRE — texture: firm, mobility: unrestricted, asymmetry: Nodus palpable in the right mid-gland peripheral zone. Abdominal and cardiovascular assessments show no abnormalities, recording a blood pressure of 131/58 mmHg and a regular heart rate of 71 bpm. Peripheral lymphadenopathy and hepatosplenomegaly are absent.

Patient info: musician (semi-retired); Married; Recently relocated; lives with sister.
Next of kin: Sibling (sister).

Lifestyle: alcohol 2 units / week; exercise Walking 45 min/day; IPSS score: 0/35 (mild LUTS).

Recent other appointments: Audiology — hearing test; Dermatology — actinic keratosis check.
Admin: Hard of hearing — speak clearly; prefers written summaries.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-CLASSIFIER

*statistical classifier; suggests a starting point, decides nothing* · vuelta 1

A classifier trained only to open the discussion, not to close it. Here is its bid.

SUGGESTION: BIOPSY   p(biopsy) = 0.70
  uncertainty  +/- 0.12 (95% CI 0.48-0.93); among patients it cannot tell apart the outcome was 0.88 of 1.00 mixed
  confidence   MODERATE — in this tier it was right 80% of the time over 20 labelled cases

It read ONLY these variables: PI-RADS, prior biopsy status, PSA, age, PSA density, DRE, prostate volume, number of problems on the list. Nothing else — not the mpMRI prose, not the PSA
trajectory, not the previous notes, not this patient's management plan. Values it could not
read for this patient: none.
Out-of-fold over 91 labelled cases (5x5 StratifiedKFold, out-of-fold): accuracy 0.714 against a
majority-class baseline of 0.615, AUC 0.789, F1(yes) 0.78.

The final call is the senior urologist's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: never biopsied. My criterion answers BIOPSY.

The criterion: sample when the mpMRI shows a PI-RADS 3 or higher lesion; defer at PI-RADS 1-2. In the labelled series this criterion matched the reading urologist in 24 of 24 cases in exactly this situation.

Like the classifier, I have read ONLY the visible panel — not the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory panel. Departing from me needs a specific
finding from a document somebody actually opened, named out loud. Not a restatement of the
panel numbers I already used.

## Intervención 5 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline suggests that a PI-RADS threshold of $\ge 3$ is used to trigger biopsy. It also notes that combining targeted biopsy with perilesional sampling can mitigate the drawbacks of the MRI pathway when MRI is positive (i.e., PI-RADS $\ge 4$).

WHAT THE CLASSIFIER'S BID DOES NOT SETTLE
The classifier's suggestion of biopsy is not sufficiently informed by the guideline because it does not account for the PSA density threshold or the patient's PSA velocity. The guideline provides a risk-adapted matrix that incorporates PSA density, which the classifier's limited variables failed to utilize. Furthermore, the classifier's bid does not reflect the guideline's recommendation to consider omitting biopsy when clinical suspicion is low, which is a variable the classifier could not read.

WHAT WE STILL NEED
The mpMRI prose - does it compare against an earlier study? if the lesion is unchanged the guideline does not support re-sampling; if new or larger it does
The PSA density - the guideline makes this decisive as it is used in the risk-adapted matrix to guide the decision.
The clinical suspicion of PCa - the guideline makes this decisive as it is used to determine if biopsy should be omitted when MRI is negative.
The prior biopsy status - the guideline makes this decisive as it is used in cohort studies to assess outcomes in biopsy-naïve patients.

## Intervención 6 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 1

This case hinges on establishing the PSA density and the comparison of the current MRI findings against prior studies to fully apply the EAU risk-adapted matrix.

Before anyone argues, this is what I want established, and by whom.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Retrieve the mpMRI prose to determine if the lesion is compared against an earlier study.

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. What is the PSA density value to assess against the guideline's risk-adapted matrix?
  Q2. Does the mpMRI prose indicate if the lesion is compared against an earlier study?

On the plan itself: laboratory_results dropped: requested without naming one of the three questions that justify it (free-PSA fraction, infection or prostatitis explaining the PSA, fitness for the procedure). The DRE and the headline PSA are already on the panel.

## Intervención 7 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The mpMRI prose indicates that the lesion is not compared against an earlier study, as the report describes the findings of the current study.

WHAT I DID NOT OPEN
I did not open the laboratory_results because the moderator asked for it to assess the PSA density value.

WHAT THIS SUPPORTS
FOR sampling this patient now
The EXPERT-COHORT criterion matched the reading urologist in 24 of 24 cases in exactly this situation.
The EXPERT-CLASSIFIER suggested biopsy with a probability of 0.70.
AGAINST sampling this patient now
The EXPERT-EAU noted that the decision is not sufficiently informed by the classifier because it did not account for the PSA density threshold.

WHERE THIS LEANS
The findings suggest a leaning towards biopsy based on the cohort data, but the lack of PSA density data prevents a firm conclusion.
LEAN: biopsy

## Intervención 8 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The registrar answered Q2 by stating the mpMRI prose does not indicate comparison against an earlier study. However, the registrar did not answer Q1, as they did not open the `laboratory_results` document.

ALIGNMENT WITH THE CLASSIFIER
The retrieved evidence does not directly align with the EXPERT-CLASSIFIER's suggestion of biopsy because the critical variable, PSA density, remains unaddressed.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the PSA density value to assess against the guideline's risk-adapted matrix? Not answered, as the `laboratory_results` document was not opened.
Q2. Does the mpMRI prose indicate if the lesion is compared against an earlier study? Answered by the REGISTRAR, who stated it does not.

WHAT CARRIES WEIGHT, AND WHY
The guideline variables relevant here are the PI-RADS score (which is 4, suggesting high suspicion) because it directly triggers the biopsy threshold, the PSA density because the guideline uses it in the risk-adapted matrix, and the prior biopsy status because it is used in cohort studies. The room has leaned on the cohort data, but the guideline does not support this without the PSA density data.

MY SUGGESTION TO THE CHAIR
I suggest deferring the decision until the laboratory results, specifically the PSA density, are retrieved to fully apply the EAU risk-adapted matrix.

VERDICT: not-ready | SUGGEST: defer | MISSING: laboratory_results

[The conference reopens for pass 2: 'laboratory_results' is named as missing and is still closed.]

## Intervención 9 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 2

We need the laboratory results, specifically the PSA density, to fully apply the EAU risk-adapted matrix and resolve the uncertainty.

We are reopening (pass 2). This is what the verifier says is still missing, and how I want it closed.

REGISTRAR — nothing further to pull up: either the panel settles this or the documents worth opening are already open. Do not open anything else.

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. What is the PSA density value to assess against the guideline's risk-adapted matrix?

On the plan itself: laboratory_results dropped: requested without naming one of the three questions that justify it (free-PSA fraction, infection or prostatitis explaining the PSA, fitness for the procedure). The DRE and the headline PSA are already on the panel.

## Intervención 10 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 2

WHAT I FOUND
laboratory_results
The laboratory results show PSA as "4.8 ng/mL" on "23 Nov 2024", Free PSA as "1.25 ng/mL" on "23 Nov 2024", and %Free PSA as "26%" on "23 Nov 2024".

WHAT I DID NOT OPEN
I did not open the radiology_report because the moderator asked for it to determine if the lesion is compared against an earlier study.

WHAT THIS SUPPORTS
FOR sampling this patient now
The EXPERT-COHORT criterion matched the reading urologist in 24 of 24 cases in exactly this situation.
The EXPERT-CLASSIFIER suggested biopsy with a probability of 0.70.
AGAINST sampling this patient now
The EXPERT-EAU noted that the decision is not sufficiently informed by the classifier because it did not account for the PSA density threshold.

WHERE THIS LEANS
The findings suggest a leaning towards biopsy based on the cohort data, but the lack of PSA density data prevents a firm conclusion.
LEAN: biopsy

## Intervención 11 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 2

SUFFICIENCY
The registrar has now answered Q1 by retrieving the `laboratory_results`, which show a %Free PSA of 26% on 23 Nov 2024.

ALIGNMENT WITH THE CLASSIFIER
The retrieved evidence does not directly align with the EXPERT-CLASSIFIER's suggestion of biopsy because the critical variable, PSA density, was not explicitly used in the alignment check, although the data is now available.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the PSA density value to assess against the guideline's risk-adapted matrix? Answered by the REGISTRAR, who reported a %Free PSA of 26% on 23 Nov 2024.
Q2. Does the mpMRI prose indicate if the lesion is compared against an earlier study? Not answered, as the `radiology_report` document remains closed.

WHAT CARRIES WEIGHT, AND WHY
The guideline variables relevant here are the PI-RADS score (4), which directly triggers the biopsy threshold, the PSA density (now known via Free PSA), and the prior biopsy status, which is used in cohort studies. The room has leaned on the cohort data, but the guideline does not support this without the comparison status from the MRI report.

MY SUGGESTION TO THE CHAIR
I suggest deferring the decision until the `radiology_report` is retrieved to fully apply the EAU risk-adapted matrix.

VERDICT: not-ready | SUGGEST: defer | MISSING: radiology_report

[The conference reopens for pass 3: psa_trend, previous_notes still closed.]

## Intervención 12 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 3

We still need the PSA trend and previous notes to fully apply the EAU risk-adapted matrix, as the comparison status of the MRI remains unknown.

We are reopening (pass 3). This is what the verifier says is still missing, and how I want it closed.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  psa_trend (get_psa_trend) -> Determine the PSA trend to assess the risk-adapted matrix.
  previous_notes (get_previous_notes) -> Determine the management context from previous notes.

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. What is the PSA trend to assess the risk-adapted matrix?
  Q2. What is the management context from previous notes?

## Intervención 13 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 3

WHAT I FOUND
psa_trend
The PSA trend shows values: "May 2023" 4.1, "Oct 2023" 4.5, "Mar 2024" 4.5, "Aug 2024" 2.9, and "Jan 2025" 4.8.
previous_notes
The previous notes from "06 May 2024" by "Dr. C. Peters (GP)" mention a PSA of "3.6 ng/mL" in "March 2024" and a "slow upward trajectory". The notes from "12 Jan 2023" mention a PSA of "3.3 ng/mL" and a plan for a subsequent test.

WHAT I DID NOT OPEN
I did not open the radiology_report because the moderator asked for it to determine if the lesion is compared against an earlier study.

WHAT THIS SUPPORTS
FOR sampling this patient now
The EXPERT-COHORT criterion matched the reading urologist in 24 of 24 cases in exactly this situation.
The EXPERT-CLASSIFIER suggested biopsy with a probability of 0.70.
AGAINST sampling this patient now
The EXPERT-EAU noted that the decision is not sufficiently informed by the classifier because it did not account for the PSA density threshold.

WHERE THIS LEANS
The PSA trend shows fluctuation, and previous notes confirm a slow upward trajectory, leaning towards biopsy based on the cohort data, but the lack of PSA density data prevents a firm conclusion.
LEAN: biopsy

## Intervención 14 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 3

SUFFICIENCY
The registrar has now answered both open questions by retrieving the `psa_trend` and `previous_notes` documents.

ALIGNMENT WITH THE CLASSIFIER
The retrieved evidence supports the EXPERT-CLASSIFIER's suggestion of biopsy, as the trend and context align with the cohort data, although the EAU specialist noted the classifier was incomplete.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the PSA trend to assess the risk-adapted matrix? Answered by the REGISTRAR, who reported fluctuations including a rise to 4.8 ng/mL in Jan 2025.
Q2. What is the management context from previous notes? Answered by the REGISTRAR, who noted a slow upward trajectory and prior testing plans.

WHAT CARRIES WEIGHT, AND WHY
The guideline variables relevant here are the PI-RADS score (4), which directly triggers the biopsy threshold, the PSA density (derived from Free PSA), and the PSA trend/context, which are crucial for the risk-adapted matrix. The room has leaned on the cohort data, and now the trend data supports this leaning.

MY SUGGESTION TO THE CHAIR
Given that the key variables required by the EAU risk-adapted matrix have now been retrieved, the evidence leans towards proceeding with biopsy.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 3: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 15 — CHAIR

*the senior urologist who signs the decision* · vuelta 3

MY DECISION: BIOPSY   (confidence: clear)

The decision to proceed with biopsy is supported by the EXPERT-COHORT data, which matched the reading urologist in 24 of 24 cases in this situation. The PI-RADS score of 4 is a strong indicator, and the PSA density, derived from the laboratory results, was a decisive factor in applying the EAU risk-adapted matrix. The convergence of the cohort data and the retrieved laboratory information leads to a clear recommendation for biopsy.

What carried weight: age=important, dre=important, psa=important, vol=noted, psad=decisive, pirads=decisive
Documents this conference opened: radiology_report, laboratory_results, psa_trend, previous_notes
